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ABSTRACT 
The study is informed by inadequate information on factors associated with the 
prevalence, incidence and mortality of cervical cancer cytological abnormalities in 
Swaziland. The aim of the study was to explore and describe factors associated with 
cervical cancer among women of reproductive age between 15 and 49 years in 
Swaziland. Quantitative descriptive design with a data extraction tool was used to 
retrospectively generate observational data from 1748 patients’ records in Mbabane 
Government Hospital from January 2014 through to December 2014. Bivariate logistic 
regression was used to establish relationship between cervical cancer and each 
explanatory variable. The overall prevalence of cervical cytology test results was 
24.9%. The combination of marital status, HIV status, ART status, age at sexual debut 
have been identified as factors associated with cervical abnormalities. Most 
importantly, the results will also serve as evidence for the development of a national 
cervical cancer screening policy and also strengthening the cancer registry in 
Swaziland. 
 
Keywords: Age; cervical cancer; cytological abnormalities; incidence, mortality; 
prevalence; reproductive; women. 
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CHAPTER 1 
ORIENTATION TO THE STUDY 
 
1.1 INTRODUCTION 
This chapter provides an orientation to the study. It outlines the background of the 
research problem, the statement of the research problem, the aim and objectives of 
the study. In addition, chapter discusses the significance of the study, the theoretical 
framework of the study, the definition of key concepts, an overview of the research 
method and an overview of the structure of the dissertation. 
 
1.2 BACKGROUND INFORMATION ABOUT THE RESEARCH PROBLEM 
Cervical cancer is the second leading cause of cancer deaths for women globally, with 
an estimated 88% of deaths occurring in the developing world. Available technologies 
have dramatically reduced mortality in high-income settings, yet cervical cancer 
receives considerably little attention on the global health policy landscape (Parkhurst 
& Vulimiri 2013:1093). Su, Wu, Scotney, Ma, Monie, Hung and Wa (2010:110) 
demonstrate that cervical cancer is the second most common cause of cancer in 
women worldwide, with approximately 510 000 new cases and 288 000 deaths 
reported annually. Every year, over half a million women die from cervical cancer 
worldwide. More than 85% of these deaths occur in low and middle-income countries. 
The World Health Organisation (2013:2) corroborates that cervical cancer is the 
second most common cancer in women affecting more than 1.4 million women 
worldwide with an increase estimates of new cases from 493,000 in 2002 to 528,000 
in 2012 and 274,000 deaths in 2002 and 266,000 deaths in 2012. In sub-Saharan 
Africa, 34.8 new cases of cervical cancer were diagnosed per 100 000 women 
annually, and 22.5 per 100 000 women die from the disease (Ferlay, Soerjomataram, 
Ervik, Dikshit, Eser, Mathers, Rebelo, Parkin, Forman, & Bray 2013:2). Cervical cancer 
is gradually becoming a rare disease in many developed countries; this is not the case 
with many countries in sub-Saharan Africa. Cervical cancer is the most common 
cancer in women in sub-Saharan Africa and second to breast cancer in northern Africa 
(Anorlu 2008:41).  
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Swaziland is not sparred from the burden related to cervical cancer among women. It 
is the most common malignant disease in women accounting for 31% (Swaziland 
Ministry of Health 2016:12). A total of 13.4 % of female respondents reported to had 
never had a screening test for cervical cancer in their lifetime and 21.7 % ever 
screened among those aged between 30 and 44 years. This translates to about one 
in every five women aged 30-49 years had ever had a screening test for cervical 
cancer (Swaziland Ministry of Health 2014:15). There are some cost effective 
interventions in low and middle income settings that can help with the management of 
cancer, including primary prevention and early detection (WHO, 2012: 27-31). The 
Papanicolaou test, commonly called the Pap test or smear, has been the gold standard 
method for cervical cancer screening worldwide and has been effective only in high-
income countries. In low-income settings, the  visually inspecting of  the cervix after 
applying a staining solution of acetic acid (VIA) or Lugol’s iodine (VILI) remained as 
most  effective method at identifying women with pre-cancerous lesions compared to 
the Pap Smear test (Cervical Cancer Action, 2012:12). 
 
1.3 STATEMENT OF THE RESEARCH PROBLEM 
Swaziland developed cervical cancer guidelines in 2013, since then cervical cancer 
screening and prevention has become an essential part of a comprehensive sexual 
and reproductive health services for women. In addition, the Swaziland National 
Cancer Registry (SNCR) has been re-established to inform response to the burden of 
cancers in the country through a systematic process.  Currently, there is inadequate 
information on the factors associated with the prevalence, incidence and mortality of 
cervical cancer cytological abnormalities. Moreover, cervical cancer most commonly 
occurring among women in the country is accounting for 31% of all cancers (Swaziland 
Ministry of Health, 2016:12). Therefore, it is important to study factors that are 
associated with cervical cancer among women of reproductive health in Swaziland. 
Guided by reliable data, the correct interventions for saving lives and improving the 
conditions of cancer patients and their families can be introduced. 
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1.4 AIM OF THE STUDY 
The aim of this study was to explore and describe factors associated with cervical 
cancer among women of reproductive age between 15 and 49 years in Swaziland.  
 
1.4.1 Research objectives 
The specific objectives for this study were:  
 To determine the baseline demographic characteristics of women of reproductive 
age between 15 and 49 years diagnosed with cervical cancer at Mbabane 
Government Hospital in Swaziland in 2014. 
 To determine the baseline clinical characteristics of women of reproductive age 
between 15 and 49 years diagnosed with cervical cancer at Mbabane Government 
Hospital in Swaziland in 2014. 
 To determine the prevalence of cervical cancer among women between 15 and 49 
years at Mbabane Government Hospital in Swaziland in 2014. 
 To determine the risk factors associated with cervical cancer among women 
between 15 and 49 years at Mbabane Government Hospital in Swaziland in 2014. 
 
1. 5 RESEARCH QUESTIONS/HYPOTHESES 
 What are the baseline demographic characteristics of women of reproductive age 
between 15 and 49 years diagnosed with cervical cancer at Mbabane Government 
Hospital in Swaziland in 2014? 
 What are the baseline clinical characteristics of women of reproductive age 
between 15 and 49 years diagnosed with cervical cancer at Mbabane Government 
Hospital in Swaziland in 2014? 
 What is the prevalence of cervical cancer among women between 15 and 49 years 
at Mbabane Government Hospital in Swaziland in 2014? 
 What are the risk factors associated with cervical cancer among women of 
reproductive age between 15 and 49 years at Mbabane Government Hospital in 
Swaziland in 2014? 
 
1.6 SIGNIFICANCE OF THE STUDY 
The proposed study will greatly benefit and assist Swaziland in several ways: 
 To help plan cervical cancer screening coverage. 
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 To support the development of a national cervical cancer screening policy.  
 To assist in planning towards strengthening the cancer registry in Swaziland.  
 To inform the development of an opportunistic integrated Sexual and Reproductive 
Health Programme. 
 
1.7 DEFINITIONS OF KEY CONCEPTS 
Age refers to the length of time that a person has lived or a thing has existed (Schwall, 
Hedge & Borman 2012:169). For the context of this study, age refers to the number of 
years women of reproductive age diagnosed with cervical cancer have lived. 
 
Cancer is a term used for the malignant, autonomous and uncontrolled growth of cells 
and tissues. Such growth forms tumours, which may invade the tissues around the 
cancer and cause new growths similar to the original cancer in distant parts of the 
body, called metastases (WHO, 2014:38). In the context of this study, cancer refers to 
malignant growth or tumour in the surrounding tissue of cervix of women of 
reproductive age between 15 and 49 years of age. 
 
Cervical pertains to many areas where tissues narrow to a neck-like passage 
(Whitlock, 2018:5). In the context of this study, cervical refers to abnormal cells in the 
lining of the cervix of women of reproductive age between 15 and 49 years of ages 
diagnosed with cancer of the cervix. 
 
Factors refer to and events, characteristics, or other definable entities that bring about 
a change in a health condition or other defined outcome (Australian Institute of Health 
and Welfare 2015:1). In the context of this study, factors refer to the following: socio-
demographic: age, place of residence, region, and marital status; reproductive: parity, 
history of contraceptives; Behavioural: sexual debut, number of lifetime partners, 
smoking, alcohol, history of STIs and Clinical: family history of cancer, menarche, 
history of STIs, serology, ART start, PAP smear results, and VIA results.  
 
Reproductive refers to being capable of producing new life or offspring (Siegel & 
Swanson, 2004:773). In this study, reproductive refers to the capability of women of 
reproductive age to conceive and have children. 
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Women refer to an adult female person (Jenkins, 2016:394). For the purposes of this 
study, women refer to adult female human beings between the ages of 15 and 49 
years diagnosed with cervical cancer. 
 
Reproductive age refers to capability of women between the ages of 15 and 49 years 
diagnosed with cervical cancer to conceive and have children (WHO, 2013:16). 
 
1.8 RESEARCH DESIGN AND METHODS 
1.8.1 Setting 
The study was conducted in the Hhohho Region at Mbabane Government Hospital, a 
referral centre for all cancer cases in Swaziland. 
 
1.8.2 Population 
Records for all patients diagnosed with cervical cancer from January 2014 through to 
December 2014 made up the study population. Data for 2014 were critical because it 
was the year when the cancer registry was established in Swaziland. The study 
findings provided baseline information for future references. Inclusion of women aged 
between 15 and 49 years is because of being in their reproductive age groups, 
sexually active and to improve screening tests for cervical cancer. 
 
1.8.3 Participant Sampling 
Census sampling includes all records that met the inclusion criteria made it possible 
to determine the prevalence of cervical cancer among women between 15 and 49 
years at the study site. 
 
1.8.4 Data Collection 
The researcher adapted the existing data extracting tool from Swaziland National 
Cancer Registry in order to ensure validity and reliability. Identified cervical cancer risk 
factors in line with programme guidelines were retrieved. Data under the following 
categories were extracted; socio-demographic: age, place of residence, region, and 
marital status; reproductive: parity, history of contraceptives; Behavioural: sexual 
debut, number of lifetime partners, smoking, alcohol, history of STIs, and clinical: 
family history of cancer, menarche, history of STIs, serology, ART start, PAP smear 
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results and VIA results. Data were read into MS Excel spreadsheet for storage and 
management.  
 
1.8.5 Data Analysis 
Data were then exported into STATA version 12.0 for analysis. In order to describe 
the data and prepare for analysis socio-demographic, behavioural, frequencies 
distributions were produced for all categorical variables and were summarised as 
proportions. Furthermore, the prevalence of clinical abnormalities in cervical cancer 
screening was established.  
 
A chi-square test was used to establish associations between the outcome variables 
and explanatory variables; age, marital status, age at first sex, age at first 
menstruation, number of live births, number of lifetime partners, smoking, alcohol, 
history of cervical cancer, HIV status, and ART status. 
 
All explanatory variables were recoded as categorical variables in order to use 
bivariate logistic and multivariate regression methods. Bivariate logistic regression 
was used to establish the relationship between cervical cancer and each explanatory 
variable using chi-square. Multivariate logistic regression was built based on bivariate 
logistic results if explanatory were below significance level of p<0.20. The significance 
level (alpha or p-value) of the study was set at 0.05. 
 
1.9 SCOPE OF THE STUDY 
The study was limited to cervical cases in Mbabane Government Hospital and those 
diagnosed from January 2014 through to December 2014 only. The study was also 
limited to extraction of patient data without an interaction with patients. Against this 
background, the researcher could not determine the sample size because the study 
sample size was dependent on the aggregated data available in the dataware-house. 
 
1.10 OVERVIEW OF THE RESEARCH METHOD 
The study looked at extraction of variables for patients diagnosed with cervical cancer 
using a structured data extraction tool and stored on excel spreadsheet. The extracted 
variables were coded in numerical values and in line with a relevant data dictionary. 
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For the purposes of this study, the researcher used observational retrospective design 
to describe factors associated with cervical cancer among women of reproductive age 
in Swaziland. Census sampling includes all records that met the inclusion criteria were 
studied to make it possible to determine the prevalence of cervical cancer among 
women between 15 and 49 years at the study site. The researcher adapted the data 
extracting tool from Cancer Registry Department to use as an existing data extraction 
instrument. 
 
1.11 ETHICAL CONSIDERATIONS 
The researcher observed all the ethical principles outlined in the University of South 
Africa (Unisa) Research Policy as well as the universal ethics principles. Ethical 
approval was obtained from the Ethics Committees of the University of South Africa. 
Permission to conduct the study was obtained from Swaziland National Health 
Research Review Board (SNHRRB). More details on ethical considerations are 
included in Chapter 3. 
 
1.12 STRUCTURE OF THE DISSERTATION 
The dissertation was structured into five chapters with a list of references and relevant 
supporting documents following the fifth chapter. The first chapter provides an 
overview of the study and articulates the context of the research problem that 
underpinned the study. The second chapter covers the literature relevant to the topic 
of the study. The third chapter described the research methodology. The fourth 
chapter focuses on the presentation and discussion of the research findings. Lastly, 
the fifth chapter provides a summary of the results, the recommendations based on 
the research findings, and the limitations of the study. 
 
1.13 CONCLUSION 
This chapter provided an introduction and background to the research problem, as 
well as the research purpose and objectives, significance and foundation of the study 
and a brief section on the research design and methodology. The next chapter will 
provide a detailed literature review. 
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CHAPTER 2  
LITERATURE REVIEW 
 
2.1 INTRODUCTION 
The previous chapter provided an introduction, background and foundation of the 
study. This chapter discusses the literature review conducted by the researcher in 
keeping with the aim of this study. The study sought to explore and describe factors 
associated with cervical cancer among women of reproductive age between 15 and 
49 years in Swaziland. Relevant literature from previous studies on factors associated 
with or contributing to cervical cancer was reviewed. The scope of this literature 
review, therefore, covers evidence from textbooks, published and unpublished 
research, scientific reports, and other credible sources of scientific work done globally, 
mainly on cervical cancer. Searches of published articles, journals and the 
proceedings of major conferences were also done. Mesh phrases used for the search 
included cervical cancer and cervical cancer Africa. Several sources were consulted, 
including medical and research textbooks, the latest relevant journals, World Health 
Organisation (WHO) publications, programme reports, the Internet and several 
Swaziland Ministry of Health reports. The Internet search engines used include Google 
scholar PubMed and Public Library of Science (PLoS). Iin addition, endnote was used 
to compile the list for literature for easy management and reference.  
 
2.2 OUTLINE OF THIS CHAPTER 
The term scientific literature refers to theoretical and research publications in scientific 
journals, reference books, text books, government reports, policy statements and 
other materials about the theory, practice and results of scientific enquiry (Garrard, 
2016:4). The outline of the chapter is as follows: 
 Cervical cancer situation at global level; 
 Cervical cancer in Africa;  
 Cervical cancer in Swaziland;   
 Risk factors associated with cervical cancer;  
 Causes for cervical cancer; 
 Cervical cancer prevention; 
 Diagnosis of cervical cancer; 
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 Cervical cancer staging; and 
 Treatment of cervical cancer; 
 Conclusion. 
 
2.3 CERVICAL CANCER SITUATION AT GLOBAL LEVEL 
According to WHO (2014:20), cervical cancer is one of the gravest threats to women’s 
lives. It is estimated that over a million women worldwide currently have cervical 
cancer. Most of these women have neither been diagnosed nor do they have access 
to treatment that could cure them or prolong their lives. In 2012, 528 000 new cases 
of cervical cancer were diagnosed, and 266 000 women died of the disease, nearly 
90% of them in low- to middle-income countries. 
 
Without urgent attention, deaths owing to cervical cancer are projected to rise by 
almost 25% over the next ten years. Cervical cancer occurs worldwide, but the highest 
incidence rates are found in Central and South America, East Africa, South and South-
East Asia, and the Western Pacific. On the contrary, over the past three decades, 
cervical cancer rates have fallen in most of the developed world, largely because of 
screening and treatment programmes (WHO, 2014:8).  
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Figure 2.1: Cervical Cancer: Estimated Age-Standardised Rate (World / Regions) per 
100,000 (AfriEDev.Info:1) 
 
 
Cervical cancer is the fourth most common cancer in women, and seventh overall, 
with an estimated 528,000 new cases in 2012 (AfriEDev.Info, 2014:1). The majority of 
the global burden (around 85%) occurs in the less developed regions, where it 
accounts for almost 12% of all female cancers. There were an estimated 266,000 
global deaths from cervical cancer in 2012 accounting for 7.5% of all female cancer 
deaths. Almost nine out of ten (87%) cervical cancer deaths occur in less developed 
regions. Mortality varies between different regions of the world, with rates ranging from 
less than 2 per 100,000 in Western Asia, Western Europe and Australia/ New Zealand 
to more than 20 per 100,000 in Middle/Central Africa 22.2, and Eastern Africa 27.6. 
Western Africa is not far behind at 18.5 (AfriEDev.Info, 2014:1). 
 
Su et al. (2010:110) demonstrate that cervical cancer is the second most common 
cause of cancer in women worldwide, with approximately 510 000 new cases and 288 
000 deaths reported annually. The World Health Organization (2012:10) corroborates 
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that worldwide, cervical cancer is the second most common malignant disease among 
women, with nearly 80% of cases arising in less developed countries. 
 
Annually, over half a million women die from cervical cancer worldwide, with more than 
85% of these deaths occurring in low- and middle-income countries. WHO (2013:2) 
corroborates that cervical cancer is the second most common cancer in women 
affecting more than 1.4 million women worldwide with an increase estimates of new 
cases from 493,000 in 2002 to 528,000 in 2012 and 274,000 deaths in 2002 and 
266,000 deaths in 2012. Moreover, the cost of the prevention vaccination is such that 
it will likely remain unavailable for most women in many parts of the world (WHO, 
2013:2). 
 
2.4 CERVICAL CANCER IN AFRICA 
Africa with a population of 267.9 million women aged 15 years and older at risk of 
developing cervical cancer, approximately 80,000 women are diagnosed with cervical 
cancer per year, and just more than 60,000 women die from the disease (Denny & 
Anorlu, 2012:1434). Cervical cancer is gradually becoming a rare disease in many 
developed countries. However, this is not the case with many countries in sub-
Saharan Africa. For example, in sub-Saharan Africa, 34.8 new cases of cervical 
cancer were diagnosed per 100 000 women annually and 22.5 per 100 000 women 
died from the disease (International Agency for Research on Cancer, 2013:2).  
 
High-risk parts of Africa, with estimated age standardised rate (ASR) of over 30 per 
100,000, include: Eastern Africa 42.7; Southern Africa 31.5; Middle/ Central Africa 
30.6; – with Western Africa on the border line of high risk at 29.3 (AfriEDev.Info, 
2014:1).  Mortality from cervical cancer in Africa is very high. Because of poor access 
to high quality screening and treatment services, the majority of cervical cancer deaths 
(85%) occur in women living in low- and middle-income countries (United Nations 
Population Fund 2011:5). Cervical cancer is a largely preventable disease, but 
worldwide it is one of the leading causes of cancer death in women. Most deaths occur 
in low- to middle-income countries (WHO 2012:37). According to IARC (2013:2), 
cervical cancer is an avoidable cause of death among women in sub-Saharan Africa.  
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Table 2.1: World countries with the top 20 highest incidence of cervical cancer in 2012 
Rank Country Age-Standardised Rate per 100,000 (World) 
1 Malawi 75.9 
2 Mozambique  65.0 
3 Comoros 61.3 
4 Zambia 58.0 
5 Zimbabwe 56.4 
6 Tanzania 54.0 
7 Swaziland 53.1 
8 Burundi 49.3 
9 Bolivia 47.7 
10 Guyana 46.9 
11 Madagascar 44.6 
12 Uganda 44.4 
13 Mali 44.2 
14 Rwanda 41.8 
15 Senegal 41.4 
16 Kenya 40.1 
17 Guinea 38.4 
17 Lesotho 38.4 
19 Suriname 38.0 
20 Fiji 37.8 
Source: GLOBOCAN 2012 v1.1 http://globocan.iarc.fr 
 
2.5 CERVICAL CANCER IN SWAZILAND 
According to Bruni, Barrionuevo-Rosas, Albero, Aldea, Serrano, Valencia, Brotons, 
Mena, Cosano, Muñoz, Bosch, de Sanjosé, and Castellsagué (2016:6), about 223 
cases of cervical cancer are annually notified among the 411 787 women at risk for 
cervical cancer (Female population aged >=15 years) in Swaziland. The crude 
incidence rate for cervical cancer is 36 per 100,000 populations. Swaziland lies in the 
regions with highest incidence rates where there is neither screening programme nor 
any anti-cancer treatment facilities that have one and two doctors per 10,000 
populations (Denny & Anorlu, 2012:1434). Swaziland Ministry of Health (2016:12) 
14 
corroborates that the country is not sparred from the burden related to cervical cancer 
among women; it is the first most common malignancy in women accounting for 31% 
of all female cancers. A total of 13.4 % of female respondents reported to had never 
had a screening test for cervical cancer in their lifetime and 21.7 % ever screened 
among those aged between 30 and 44 years. Therefore, this translates to about one 
in every five women aged 30-49 years had ever had a screening test for cervical 
cancer (Swaziland Ministry of Health, 2014:15). 
 
Table 2.2: Cervical cancer incidence in Swaziland, Southern Africa and World 
(estimations for 2012) 
Indicator Swaziland  Southern Africa World 
Annual number of new cancer 
cases  
223  8,652  527,624 
Crude incidence rate per 100,000 
women per year 
36.0 29.3 15 
Age-standardised incidence rate 
per 100,000 women per year. 
53.1  31.5  14.0 
Cumulative risk (%) at 75 years old  5.0  3.1  1.4 
Sources: GLOBOCAN 2012 v1.2 Available from: http://globocan.iarc.fr. 
 
As indicated in Table 2.2, available reports that cervical cancer morbidity was 
estimated at 36.0/100 000 women per year. On another note, cervical cancer mortality 
was estimated at 19.1//100 000 women per year as indicated in Table 2.3. 
Table 2.3: Cervical cancer mortality in Swaziland (estimations for 2012) 
Indicator Swaziland  Southern Africa World 
Annual number of deaths 118 4,721 265,672 
Crude mortality rate per 100,000 
women per year 
19.1 16.0 7.6 
Age-standardised mortality rate per 
100,000 women per year 
31.0 17.9  6.8 
Cumulative risk (%) at 75 years old  3.0  1.9 0.8 
Sources: GLOBOCAN 2012 v1.2 Available from: http://globocan.iarc.fr. 
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In response to cervical cancer being leading among female cancers and also 
increasing cases, Swaziland developed cervical cancer guidelines in 2013. Since then, 
cervical cancer screening and prevention have become an essential part of a 
comprehensive sexual and reproductive health services for women. In addition, the 
Swaziland National Cancer Registry (SNCR) has been re-established to inform 
response to the burden of cancers in the country through a systematic process. 
 
2.6 RISK FACTORS ASSOCIATED WITH CERVICAL CANCER  
According to the Alliance for Cancer Prevention (2014:1), a risk factor is anything that 
increases a person's chance of developing cancer. Although risk factors often 
influence the development of cancer, most do not directly cause cancer. Some people 
with several risk factors never develop cancer, while others with no known risk factors 
do. 
 
Age at sexual debut, lifetime number of sexual partners, history of sexually transmitted 
infections, sexual activity, HIV and human papillomavirus (HPV) are linked to the 
likelihood of becoming infected with cervical cancer (The Lancet, 2017: 849).  Long-
term use of oral contraceptives is associated with increased risk; women with HIV and 
AIDS are also at increased risk of cervical cancer. In the same vein, Raghavendra, 
Nitturu, and Kamble (2014:8) attest that women with sexual behavioural variables 
have higher odds of cervical cancer and these associations were found to be 
statistically significant. These variables include early age at first coitus, the time 
interval since first exposure, history of extra marital sex in husband and wife; 
reproductive variables like parity, lack of genital and menstrual hygiene, previous 
history of sexually transmitted diseases and lastly, dietary factors like lower frequency 
of fruit consumption.  
 
According to Bahmanyar, Paavonen, Naud, Salmerón, Chow, Apter, Kitchener, 
Castellsagué, Teixeira, Skinner, and Jaisamrarn (2012:443), their analysis in the 
Papilloma Trial against cancer in young adults (PATRICIA) showed a significant 
association between several behavioural risk factors. The latter include not married or 
living with a partner, smoking, young age at first sexual intercourse, higher number of 
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sexual partners, longer duration of hormonal contraceptive use, condom use, and 
history of STIs, and infection with cervical cancer. 
 
The study will review factors that include Human papilloma virus (HPV), immune 
system deficiency, history of alcohol, first menstrual age, history of STIs, history of 
smoking, age, onset of sexual intercourse activity, number of lifetime partners, history 
of contraceptives, and multiple pregnancies. The study will also focus on these factors 
because in 2014, the Swaziland Cancer Registration tools were limited to these 
factors. 
 
2.7 CAUSES OF CERVICAL CANCER  
2.7.1 Human papillomavirus (HPV) infection 
Cervical cancer, caused by sexually acquired infection with HPV, continues to be a 
public health problem worldwide as it claims the lives of more than 270,000 women 
every year (UNFPA, 2011:5). This virus is most commonly passed from person to 
person during sexual activity. According to Colombo, Carinelli, Colombo, Marini, Rollo, 
and Sessa (2012:vii27), HPV is detected in 99% of cervical tumours, in particular the 
oncogenic subtypes such as HPV 16 and 18. 
 
There are different types, or strains, of HPV, and some strains are more strongly linked 
with certain types of cancers. Bahmanyar et al. (2012:441), in the PATRICIA trial 
conducted in a number of countries, corroborate that HPV is the causal agent in 
virtually all cervical pre-cancer and cancer. Currently, 13 HPV types are believed to 
be carcinogenic, of which types HPV-sixteen and HPV-eighteen cause approximately 
70% of cervical cancer. Infection with HPV types is a necessary, although not 
sufficient, cause of almost all cases of cervical cancer. The progression from HPV 
infection to cervical cancer occurs over a series of 4 steps: HPV transmission, acute 
HPV infection, persistent HPV infection leading to precancerous changes, and 
invasive cervical cancer (Vesco, Whitlock, Eder, Burda, Senger & Lutz, 2011: 698). 
 
2.7.2 Immune system deficiency 
A lowered immune system can be caused by immune suppression from corticosteroid 
medications, organ transplantation, treatments for other types of cancer, or from HIV 
and AIDS. Women who are HIV positive are at particular risk of progression to invasive 
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cervical cancer (The Lancet, 2017:856). In a study in South Africa, Shimange (2017: 
52) corroborates that owing to the HIV pandemic, sero-positive patients presented with 
invasive cervical carcinoma ten years earlier than their sero-negative counterparts.  
 
According to WHO (2014:42), cervical cancer is a defining illness of AIDS, that women 
living with HIV and other immunocompromised women have a higher prevalence of 
HPV (the risk of infection increases with the degree of immunosuppression) and a 
higher prevalence of persistent HPV infection and infection with multiple high-risk HPV 
types. Consequently, this increased susceptibility to HPV infection leads to a greater 
risk of pre-cancer and cancer at younger ages, which increases with the degree of 
immunosuppression; an increased risk of developing invasive disease up to ten years 
earlier than in women not infected with HIV; and more frequent presentation with 
advanced disease with smaller chance of survival for five years. 
 
2.7.3 History of sexually transmitted infections (STIs) 
Women who have genital herpes have a higher risk of developing cervical cancer. Co-
infection with other sexually transmitted agents, such as Chlamydia trachomatis and 
herpes simplex virus, may be associated with risk for HPV infection (Vesco et al., 
2011:699).  
 
2.7.4 Age 
Girls younger than 15 years rarely develop cervical cancer. The risk goes up between 
the late teens and middle thirties. Women over 40 years remain at risk and need to 
continue having regular cervical cancer screenings, which include both a Pap test and 
HPV test. Teschendorff, Menon, Gentry-Maharaj, Ramus, Weisenberger, Shen, 
Campan, Noushmehr, Bell, Maxwell, and Savage (2010:442) conducted a study on 
deoxyribonucleic acid methylation (DNAm) profiling of 48 age-matched cervical smear 
samples from premenopausal women with normal smears (HPV-positive and 
negative) and smears exhibiting dysplasia (all HPV-positive; Supplemental material). 
They verified that the age of samples with dysplasia did not differ from the normal 
smears (Wilcoxon test, P = 0.86). Despite the relatively small sample size and narrow 
age range of this premenopausal sample set, it was found that Polycomb group 
proteins target genes (PCGTs) and 69 age-PCGT Carcinogenic potential group (CpG) 
subset were preferentially hyper-methylated with age. 
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2.7.5 Age at sexual debut 
Delaying commencement of sexual activity and avoiding early and repeated birth are 
strong considerations in the fight against cervical cancer options which are hardly open 
to girl ‘brides’, vulnerable to intimidation and sexual violence (AfriEDev.Info, 2014:1). 
According to Plummer, Peto and Franceschi (2012:2640), in International 
Collaboration of Epidemiological Studies of Cervical Cancer that the odds ratios for 
invasive cervical carcinoma were approximately proportional to the square of time 
since first intercourse (exponent 1.95, 95% CI: 1.76–2.15) up to age 45. First cervical 
infection with HPV often occurs soon after first sexual intercourse. Therefore, early 
age at first intercourse is a reasonable proxy for early age at first exposure to HPV. 
 
2.7.6 Oral contraceptives 
Some research studies suggest that oral contraceptives may be associated with an 
increase in the risk of cervical cancer. Castellsagu, Díaz, Vaccarella, de Sanjosé, 
Muñoz, Herrero, Franceschi, Meijer, and Bosch (2011: 1023) conducted  in a study on 
copper intrauterine contraceptive device (IUD) and cervical cancer, after adjusting for 
relevant covariates, a strong inverse association was found between ever use of 
copper IUDs and cervical cancer (odds ratio 0·55, 95% CI 0·42–0·70; p<0·0001). This 
suggested that copper IUD use might act as a protective cofactor in cervical 
carcinogenesis. 
 
2.7.7 Smoking 
According to Roura, Castellsagué, Pawlita, Travier, Waterboer, Margall, Bosch, De 
Sanjosé, Dillner, Gram, and Tjønneland (2014: 463), tobacco smoking is a cited cause 
of cervical cancer, but whether it causes cervical malignancy independent of HPV 
infection is unclear. Here, strong associations were found between most measures of 
tobacco smoking and the risk of cervical intraepithelial neoplasia of Grade 3/carcinoma 
in situ and invasive cervical cancer, after taking into account past exposure to HPV 
infection. Quitting smoking was associated with a two-fold risk reduction. The findings 
confirm the role of tobacco smoking in cervical carcinogenesis and show that quitting 
the habit has important benefits for cancer protection.  
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2.8 Causes for cervical cancer 
According to the Anticancer Fund (2012:5), it has become clear that essentially all 
cervical cancers are caused by certain types of HPV infection, caused by sexual 
contact or even by skin-to-skin contact. HPV is very frequent in the general population 
that almost all adult women have at some time contracted HPV. However, in the 
overwhelming majority of cases, HPV infection resolves within six months to two years 
without causing any signs of disease. A persistent infection with the so-called high-
risk (carcinogenic, cancer causing) HPV types, notably HPV types 16 and 18, which 
are the most common types found in cervical cancer cases worldwide, is necessary 
for cancer to develop. However, this is not sufficient as the development of cervical 
pre-cancerous lesions and cervical cancer takes several years (decades) to occur. 
Bahmanyar et al. (2012:441) underscore that HPV is the causal agent in virtually all 
cervical pre-cancer and cancer. Currently, 13 HPV types are believed to be 
carcinogenic, of which types HPV-16 and HPV-18 cause approximately 70% of 
cervical cancer.  
 
2.9 Cervical cancer prevention 
Well-organised cervical screening programmes or widespread good quality cytology 
can reduce cervical cancer incidence and mortality. The introduction of HPV 
vaccination could also effectively reduce the burden of cervical cancer in the coming 
decades. According to the Anticancer Fund (2012:5), when detected early, the 
treatment of cervical cancer is simple and effective. Therefore, the main risk factor for 
life threatening cervical cancer is failing to have regular gynaecological examinations 
and Pap smears. Vesco et al. (2011:699) argue that one reason why cytological 
screening for cervical cancer has been so successful is that cervical cancer does not 
develop suddenly, it is preceded by precancerous changes of the cervix that are 
known as cervical intraepithelial neoplasia (CIN). 
 
According to WHO (2014:52), a comprehensive programme includes three 
interdependent components: primary, secondary and tertiary prevention. The 
interventions included in each component are described in figure 2.2. 
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Figure 2.2: The WHO comprehensive approach to cervical cancer prevention and 
control: Overview of programmatic interventions over the life course to prevent HPV 
infection and cervical cancer (WHO, 2013: 52). 
 
 
In the HPV vaccination era, it is expected that the cervical cancer incidence will be 
reduced, especially in those developed countries where large-scale immunization has 
been introduced. Most developed countries have introduced HPV vaccines into routine 
vaccination programmes and more than 60 million doses have already been 
distributed in 2010, which could guarantee a protection rate of ∼70% (Colombo, 
Carinelli, Colombo, Marini, Rollo & Sessa, 2012: vii27). 
 
2.10 Diagnosis of cervical cancer 
The Anticancer Fund (2012: 5) indicates that early detection of cervical cancer can 
easily be made by an examination of swaps or smears from the cervix surface, 
obtained during a gynaecological examination. Cervical cancer must be suspected 
when there are abnormalities upon gynaecological examination. The latter include 
severe abnormalities in cervical smears; there is bleeding outside of menstruation 
periods; and there is bleeding after sexual intercourse. According to Colombo et al 
(2012: vii27), the WHO recognises three categories of epithelial tumours of the cervix: 
squamous, glandular (adenocarcinoma), and other epithelial tumours, including 
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neuroendocrine tumours and undifferentiated carcinoma. Squamous cell carcinomas 
account for ∼70%–80% of cervical cancers and adenocarcinomas for 10%–15%. Early 
cervical cancer is often asymptomatic while locally advanced disease could cause 
symptoms, including abnormal vaginal bleeding, also after coitus, discharge, pelvic 
pain, and dyspareunia. Some early cancers are not appreciable and even deeply 
invasive tumours may be somewhat deceptive on gross examination. If examination 
is difficult or there is uncertainty about vaginal/ parametrial involvement, this should 
be done under anaesthesia together with a radiotherapist. 
 
According to Vesco et al. (2011:699), cervical cytology results are not diagnostic of 
cervical intraepithelial neoplasia (CIN) or cancer, biopsy and histologic confirmation 
are required for diagnosis. The above statement means that for countries to 
successfully manage cervical cancer, guidelines should articulate screening 
procedure, including when to start and stop. 
 
The Anticancer Fund (2012:6) postulates that diagnosis of cervical cancer is based on 
clinical examination; Pap smear test; colposcopy; histopathological examination; 
Bethesda cytological examination; routine laboratory examination of blood and urine, 
and also medical imaging examination.  
 
2.11 STAGING OF CERVICAL CANCER 
According to Colombo et al. (2012:vii28), the cervical cancer Féderation Internationale 
de Gynécologie etd’Obstétrique (FIGO) classification is based on clinical examination. 
The FIGO classification is based on tumour size, vaginal or parametrial involvement, 
bladder/rectum extension, and distant metastases. It requires radiological imaging 
such as chest X-ray and intravenous pyelogram. A comparison between The American 
Joint Committee on Cancer (TNM) classification and FIGO staging is shown in Table 
2.2. 
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Table 2.4: Comparison of TNM categories and FIGO staging 
TNM 
categories 
FIGO 
stages 
 
TX Primary   Tumour cannot be assessed. 
T0   No evidence of primary tumour. 
Tisb   Carcinoma in situ (pre-invasive carcinoma). 
T1 I Cervical carcinoma confined to uterus (extension to 
corpus should be disregarded). 
T1ac  IA Invasive carcinoma diagnosed only by microscopy. 
Stromal invasion with a maximum depth of 5.0 mm 
measured from the base of the epithelium and a horizontal 
spread of ≤7.0 mm. Vascular space involvement, venous 
or lymphatic, does not affect classification. 
T1a1 IA1 Measured stromal invasion ≤3.0 mm in depth and 
≤7.0 mm in horizontal spread. 
T1a2 IA2 Measured stromal invasion >3.0 mm and ≤5.0 mm with a 
horizontal spread of ≤7.0 mm. 
T1b IB Clinically visible lesion confined to the cervix or 
microscopic lesion >T1a/IA2. 
T1b1 IB1 Clinically visible lesion ≤4.0 cm in greatest dimension. 
T1b2 IB2 Clinically visible lesion >4.0 cm in greatest dimension. 
T2 II Cervical carcinoma invades beyond uterus but not to 
pelvic wall or to lower third of vagina. 
T2a IIA Tumour without parametrial invasion. 
T2a1 IIA Clinically visible lesion ≤4.0 cm in greatest dimension. 
T2a2 IIA2 Clinically visible lesion >4.0 cm in greatest dimension. 
T2b IIB Tumour with parametrial invasion. 
T3 III Tumour extends to pelvic wall and/or involves lower third 
of vagina, and/or causes hydronephrosis or non-
functioning kidney. 
T3a IIIA Tumour involves lower third of vagina, no extension to 
pelvic wall. 
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T3b IIIB Tumour extends to pelvic wall and/or causes 
hydronephrosis or non-functioning kidney. 
T4 IV The carcinoma has extended beyond the true pelvis or 
has involved (biopsy proven) the mucosa of the bladder 
or rectum. A bullous edema, as such, does not permit a 
case to be allotted to stage IV. 
T4a  IVA Spread of the growth to adjacent organs. 
T4b IVB Spread to distant organs. 
Source: Colombo, N., Carinelli, Colombo, A., Marini, Rollo and Sessa (2012:vii28). 
Available from http://annonc.oxfordjournals.org  
 
2.12 TREATMENT OF CERVICAL CANCER 
2.12.1 Primary treatment 
According to Colombo et al. (2012: vii29), depending on stage, primary treatment 
consists of surgery, radiotherapy, or a combination of radiotherapy, and 
chemotherapy. Definitive radiation therapy should consist of pelvic external beam 
radiation with high-energy photons and intracavitary brachytherapy, and must be 
administered at high doses (>80–90 Gy) and in a short time (<55 days), with the best 
technological resources available. 
 
Table 2.5: Cervical cancer treatment according to stage 
Stage  Treatment  Issue 
IA1 Conization or simple hysterectomy 
± salpingo-ophorectomy and 
pelvic lymphadenectomy (PLND) if 
lymphovascular space invasion 
(LVSI) 
Conservative surgery 
IA2 Conization/ radical trachelectomy 
or modified radical hysterectomy 
and PLND 
Adjuvant computed tomography/, 
radiation therapy (CT/RT) if risk 
factors (LVSI, G3, positive 
resection margins, multiple 
nodes) 
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IB1, IIA Radical hysterectomy and PLND Adjuvant CT/RT if risk factors 
(LVSI, G3, positive resection 
margins, multiple nodes) 
IB2, IIB–IV Combination CT/RT with cisplatin  Neoadjuvant chemotherapy 
(NACT) to large bulky tumours 
prior CT/RT 
Source: Colombo et al (2012:vii28). Available from http://annonc.oxfordjournals.org 
Pelvic lymphadenectomy (PLND); lymphovascular space invasion (LVSI); computed 
tomography (CT); neoadjuvant chemotherapy (NACT); radiation therapy (RT). 
 
2.12.2 Management of advanced/metastatic disease 
Patients with metastatic or recurrent cervical cancer are commonly symptomatic. The 
role of chemotherapy in such patients is palliative, with the primary objective to relieve 
symptoms and improve quality of life (Colombo et al., 2012:vii30). The response rates 
after previous chemotherapy are worse compared with chemotherapy naïve patients. 
Cisplatin is considered the single most active cytotoxic agent. Overall, the duration of 
the objective response to cisplatin in patients with metastatic or recurrent disease 
remains disappointing and survival in such patients is only ∼7 months. There is no 
clear dose response effect. Cisplatin-based combination therapy, such as cisplatin–
paclitaxel and cisplatin–topotecan, has been extensively investigated in clinical trials. 
Only the cisplatin–topotecan combination reported an overall survival advantage 
compared with monotherapy.  
 
2.12.3 Response evaluation and follow-up 
According to Colombo et al. (2012:vii31), no definitive agreement exists on the best 
post-treatment surveillance. Computed tomography (CT) or positron emission 
tomography (PET) scan should be performed as clinically indicated. A clinical visit with 
gynaecological examination including Pap smear is usually performed every three 
months for the first two years, every six months for the next three years and yearly 
thereafter. Marth, Landoni, Mahner, McCormack, Gonzalez-Martin and Colombo 
(2017:iv81) highlight that patients should return to annual population-based general 
physical and pelvic examinations after five years of recurrence-free follow-up. 
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2.13 CONCLUSION 
Cervical cancer remains a huge health problem and is driven by an array of risk 
factors. These include socio-demographic, behavioural, and clinical. In line with the 
aim of the study, namely, to explore and describe factors associated with cervical 
cancer among women of reproductive age between 15 and 49 years in Swaziland the 
review searched for literature on categories of risk factors as highlighted from chapter 
2.6 to 2.7.2. The purpose of this review was to look at the situation of cervical cancer 
from a global level, down to African perspective before focusing on Swaziland 
situation. Different guidelines were further reviewed to establish ways of prevention, 
causes, diagnosis, staging, and treatment for cervical cancer. In summary, the 
situation of cervical cancer from a broad to the local perspective, including risk factors 
is well documented in the literature. 
 
28 
CHAPTER 3  
RESEARCH METHODOLOGY 
 
3.1 INTRODUCTION 
The study was conducted with the aim of describing and exploring factors associated 
with cervical cancer among women of reproductive age between 15 and 49 years in 
Swaziland. This was done with the view of recommendations on which factors should 
be the focus for the country in the fight against cervical cancer. In this chapter, 
research design and methodology of the study are discussed in detail including, study 
population, sample, the data collection tool, data collection process, data 
management, ethical considerations, reliability, validity, and analysis. 
 
3.2 METHODOLOGICAL FOUNDATION 
The study was conducted within the objectivist epistemological perspective. According 
to Yilmaz (2013:312), the objectivist epistemology seeks to develop explanatory 
universal laws in social behaviours by statistically measuring what it assumes to be a 
static reality. It emphasises the measurement and analysis of causal relationships 
between isolated variables within a framework, which is value-free, logical, 
reductionist, and deterministic, based on a priori theories. A quantitative approach 
endorses the view that psychological and social phenomena have an objective reality 
that is independent of the subjects being studied. 
 
3.3 RESEARCH DESIGN 
Grove, Burns and Gray (2013:43) assert that a research design is a pattern that should 
be followed to maximise control over factors that could interfere with a study’s 
outcomes. The purpose of a descriptive design is to identify patterns of variables, to 
describe and define variables, to identify initial links among variables, and to compare 
and contrast on variables of interest. For the purposes of this study, the researcher 
used an observational retrospective design to describe factors associated with cervical 
cancer among women of reproductive age in Swaziland. It attempted to “connect the 
dots” by identifying factors associated with cervical cancer among women of 
reproductive age. 
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3.3.1 Quantitative research 
Quantitative research can be conceptually divided into two types: descriptive and 
associational. Grove et al (2013:43) maintain that a research design is a pattern that 
should be followed to maximise control over factors that could interfere with a study’s 
outcomes. The purpose of a descriptive design is to identify patterns of variables, to 
describe and define variables, to identify initial links among variables, and to compare 
and contrast on variables of interest. Yilmaz (2013:311) defines quantitative research 
as a type of empirical research into a social phenomenon or human problem, testing 
a theory consisting of variables which are measured with numbers and analysed with 
statistics in order to determine if the theory explains or predicts phenomena of interest. 
In view of the above literature, for the purpose of this study, the researcher used 
quantitative, analytical, associational, observational, and retrospective design to 
describe factors associated with cervical cancer among women of reproductive age in 
Swaziland. A statistician was consulted in development of the questionnaire, data 
capturing and analysis. 
 
This study was quantitative in nature because it explored and described factors 
associated with cervical cancer among women of reproductive age between 15 and 
49 years in Swaziland. The study only looked at extracted variables of patients 
diagnosed with cervical cancer by using a structured data extraction tool and stored 
on MS Excel spreadsheet. The extracted variables were coded in numerical values 
and in line with a relevant data dictionary. 
 
3.4 RESEARCH METHODS 
3.4.1 Population 
The researcher needed to know what characteristics the study participants should 
possess, and clarify the group to whom study results can be generalised by identifying 
the population to be studied. A population is all the individuals or objects with common, 
defining characteristics (Polit & Beck, 2010:75). The study population included records 
of all women diagnosed with cervical cancer at Mbabane Government Hospital from 
January 2014 through to December 2014. Data from 2014 was used because 
Swaziland had just developed cervical cancer guidelines and also cervical cancer 
screening and prevention become an essential part of a comprehensive sexual and 
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reproductive health services for women. In addition, the Swaziland National Cancer 
Registry (SNCR) was re-established to inform response to the burden of cancers in 
the country. The study focused on women aged between 15 and 49 years because of 
being in their reproductive age groups, sexually active and to improve screening tests 
for cervical cancer. 
 
3.4.2 Inclusion criteria 
The inclusion criteria were as follows: 
 Clinical records of all women who tested for cervical cancer between January 2014 
and December 2014. 
 Women aged between 15 and 49 years old and diagnosed with cervical cancer at 
Mbabane Government Hospital. 
 
3.4.3 Exclusion criteria 
Conversely, the exclusion criteria were as follows: 
 Clinical records of all women who did not test for cervical cancer between January 
2014 and December 2014. 
 Records of all women whose records were incomplete. 
 Women aged below 15 years and above 49 years old diagnosed with cervical 
cancer at Mbabane Government Hospital. 
 
3.4.4 Sample 
According to Polit and Beck (2010:75), researchers typically collect data from a 
sample, which is a subset of the population. A sample is clearly more practical and 
less costly than collecting data from an entire population. A carefully selected sample 
can provide data representative of the population from which it is drawn. However, the 
risk is that the sample might not adequately reflect the population’s traits. All the 
records of women between ages of 15 and 49 years diagnosed with cervical cancer 
constituted the sample. Data from the patients’ files and registers were extracted and 
stored in a database for statistical analysis. 
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3.4.5 Sampling 
According to Bhattacherjee (2012:65) Sampling is the statistical process of selecting 
a subset (called a “sample”) of a population of interest for purposes of making 
observations and statistical inferences about that population. There are two main types 
of sampling, namely, probability and non-probability sampling. Non-probability 
sampling is a sampling technique in which some units of the population have zero 
chance of selection or where the probability of selection cannot be accurately 
determined (Bhattacherjee, 2012:69). The researcher employed non-probability 
sampling because cervical cancer was diagnosed at the referral hospital where 
records of all patients who tested positive for cervical cancer from January 2014 
through to December 2014 constituted the sample. 
 
3.4.6 Sampling method 
According to Dattalo (2010:1), although random sampling is considered by many 
researchers as the gold standard methodological procedure for maximising external 
validity and optimising sample size, in practice, random sampling often is difficult to 
implement. Therefore, non-probability sampling methods used to balance a sample’s 
composition in terms of characteristics and diversity. The study population included 
records of all women diagnosed with cervical cancer at Mbabane Government Hospital 
from January 2014 through to December 2014. Census sampling whereby all records 
that meet the inclusion criteria were studied to make it possible to determine the 
prevalence of cervical cancer among women between 15 and 49 years at the study 
site. 
 
3.4.7 Research setting 
Polit and Beck (2010:223) assert that data for quantitative studies sometimes are 
collected in real-world settings, such as in clinics or people’s homes. Other studies are 
conducted in highly controlled environments established for research purposes.  
Another important design decision concerns how many different sites will be involved 
in the study.  
The study was conducted at Mbabane Government Hospital, a referral centre for all 
cancer cases in Swaziland as mandated by the Ministry of Health in Swaziland. Data 
collected in 2014 were critical because it was the year when the cancer registry was 
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established in Swaziland so that findings provided baseline information for future 
reference. 
 
3.4.8 Ethical issues related to sampling 
In the non-probability sampling, data were extracted from patients’ files and 
registers. Approval to conduct the study was sought in the following manner: 
 An approval letter to conduct the study was requested from the Swaziland 
National Health Research Review Board (SNHRRB). 
 An ethical clearance certificate was obtained from the University of South Africa 
Department of Health Studies’ Higher Degrees Committee 
 Permission letter to conduct the study was requested from Mbabane Government 
Hospital. 
 Permission letter to conduct the study was requested from Sexual Reproductive 
Health Unit (SRHU). 
 
3.5 DATA COLLECTION 
According to Polit and Beck (2010:339), data collection concerns the gathering of data 
to address research questions. A variety of quantitative data collection approaches 
exist; the primary methods are self-reports, observations, review of existing data, and 
bio-physiologic measurements. In this study data from a clinic register, other patients’ 
files and cards were extracted.   
 
3.5.1 Description of data collection tool 
Existing records are an important data source for nurse researchers. A wealth of data 
gathered for other than research purposes can be fruitfully exploited to answer 
research questions. Hospital records, patient charts, care plan statements, and the 
like all constitute rich data sources to which nurse researchers may have access (Polit 
& Beck, 2010:338). 
 
Quantitative methods require the researcher to use a pre-constructed standardised 
instrument or pre-determined response categories into which the participants’ varying 
perspectives and experiences are expected to fit (Yilamz, 2013:313). For the purposes 
of this study, an existing data extraction instrument from Ministry of Health Cancer 
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Registry Department was used to extract data. Permission to use the tool was granted 
by the department. The data extraction tool has cervical cancer patients’ variables of 
interest under different categories, namely, socio-demographic, behavioural, 
reproductive, and clinical risk factors. The hospital uses a number of tools to store 
patients’ records. These include patients’ files, cards and patient-care registers. 
The following categories and variables were identified in the different source 
documents:  
 Socio-demographic: age, place of residence, region, and marital status;  
 Reproductive: parity, history of contraceptives;  
 Behavioural: sexual debut, number of lifetime partners, smoking, alcohol, history 
of STIs; and  
 Clinical: family history of cancer, menarche, history of STIs, serology, ART start, 
PAP smear results, and VIA results. 
 
3.5.2 Data collection procedure 
Identified cervical cancer risk factors in line with programme guidelines were retrieved 
as per the different variables in the extraction tool. Cervical cancer patients’ variables 
of interest including socio-demographic, behavioural, reproductive and clinical risk 
factors were extracted from patients’ records including; patients files, cards and 
patient-care registers. 
Data under the following categories were extracted; Socio-demographic: age, place of 
residence, region, and marital status; Reproductive: parity, history of contraceptives; 
Behavioural: sexual debut, number of lifetime partners, smoking, alcohol, history of 
STIs and Clinical: family history of cancer, menarche, serology, ART start, PAP smear 
results and VIA results. Data were extracted and stored in excel spreadsheet then 
exported into STATA 13.0 (Stata corp.college station, Texas, USA) for analysis 
 
3.6 DATA MANAGEMENT AND ANALYSIS 
Data were stored in MS Excel spreadsheet after extraction then exported into STATA 
13.0 for cleaning before analysis. Study unique identifiers were captured to maintain 
anonymity of participants and security was ensured by password protection and 
encryption according to Good Data Management Practices (GDMP) and Good Clinical 
Practices (GCP).  Data were further checked for possible errors and missing values 
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through running of frequencies, such that any issues were addressed by going back 
to the data sources to verify the data. The researcher was guided by the supervisors 
and a qualified statistician as an expert in the field to ensure GDMP and GCP. 
 
Percentages and proportions were used to estimate the prevalence of reproductive 
women diagnosed with cytological abnormalities from January 2014 through to 
December 2014. The prevalence of cytological abnormalities diagnosed in women 
aged 15 to 49 years of age was compared using a chi-square test. The strength and 
magnitude of association of the factors related to cervical cancer screening 
programme were tested using Spearman’s rho correlation test.  The significance level 
(alpha or p- value) of this study was be set at 0.05. This means that if a mean or a 
proportion from a sample is likely to occur more than alpha then the researcher fails 
to reject the null hypothesis. 
 
3.7 VALIDITY AND RELIABILITY OF THE STUDY TOOLS 
According to Yilmaz (2013:317), reliability means consistency or the degree to which 
a research instrument measures given variable consistently every time it is used under 
the same condition with the same subjects. It is important to note that reliability applies 
to data not to measurement instruments. Validity refers to the accuracy and 
trustworthiness of instruments, data, and findings in research. Nothing in research is 
more important than validity (Bernard, 2010:53). 
 
In order to ensure validity and reliability, the researcher adapted the data extracting 
tool from Cancer Registry Department to use as an existing data extraction instrument. 
A data quality system was put into place to ensure the extraction of quality data for 
analysis. Data collection was standardised, where a standard operating procedure 
was developed with instructions detailing how data would be extracted and stored and 
maintained. Periodical review of data collection was undertaken by the researcher to 
help to identify gaps in data extraction. 
 
3.8 ETHICAL CONSIDERATIONS 
The study was not in contact with patients. Instead, data were extracted from patients’ 
files and registers. Approval to conduct the study was sought in the following manner; 
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 An approval letter to conduct the study was requested from the Swaziland National 
Health Research Review Board (SNHRRB). 
 An ethical clearance certificate was obtained from the University of South Africa 
(Unisa) Department of Health Studies’ Higher Degrees Committee. 
 Permission letter to conduct the study was requested from Mbabane Government 
Hospital. 
 Permission letter to conduct the study was requested from Sexual Reproductive 
Health Unit (SRHU). 
The researcher did not foresee any risks because patients’ identifiers were not 
extracted, but instead, a study identification number was used to link patients’ records 
with data. Most importantly, the researcher worked with knowledgeable research 
officers who were also trained in ethical procedures before conducting the study. 
 
The researcher has received training on procedures to protect participant 
confidentiality and GCP. The researcher worked with knowledgeable research officers 
who were also trained on the data extraction tool and on GDMP to ensure adherence 
to ethical issues before conducting the study. They were also made to sign 
confidentiality agreement by the researcher as part of GCP. Patient health information 
(PHI) was protected, for example; name, telephone number, residential address or 
other personal details did not appear on any of the extracted records. No patient 
records left the hospital. Even during the data extraction exercise, a separate room 
was used, and records returned to filing room upon finish.  Extracted data in the 
electronic tool were password-protected to prevent unnecessary interference. 
There was no gift or any monetary arrangements in the study; only data were extracted 
from patients’ files and registers or records at no cost. 
 
3.9 CONCLUSION 
This chapter described the methodology followed by the researcher to address the 
research question. It provided the rationale and motivation for the selected 
methodology. It also examined how the ethical principles were observed to collect, 
manage, analyse data to produce results for the study. In the next chapter, the results 
of the study are presented and discussed. 
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CHAPTER 4  
ANALYSIS, PRESENTATION AND DESCRIPTION OF THE 
RESEARCH FINDINGS 
 
4.1 INTRODUCTION 
In chapter 3 methodology was described, including rationale and motivation for the 
selected methodology. In this chapter, the main research findings of the study are 
presented and discussed. The discussion will focus on the research objectives of the 
study and compare the research findings with existing literature. These results are 
introduced by the presentation and discussion of the characteristics of the 
respondents. A conclusion is provided at the end of the chapter. The specific 
objectives for this study were as follows:  
 To determine the baseline demographic characteristics of women of reproductive 
age between 15 and 49 years diagnosed with cervical cancer at Mbabane 
Government Hospital in Swaziland in 2014. 
 To determine the baseline clinical characteristics of women of reproductive age 
between 15 and 49 years diagnosed with cervical cancer at Mbabane Government 
Hospital in Swaziland in 2014. 
 To determine the prevalence of cervical cancer among women between 15-49 
years at Mbabane Government Hospital in Swaziland in 2014. 
 To describe risk factors associated with cervical cancer among women between 
15-49 years at Mbabane Government Hospital in Swaziland in 2014. 
 
 
4.2 DATA MANAGEMENT AND ANALYSIS 
Data were stored in MS Excel spreadsheet after extraction then exported into STATA 
version13.0 for cleaning before analysis. Study unique identifiers were captured to 
maintain anonymity of participants and security was ensured by password protection 
and encryption according to GDMP and GCP.  Data were further checked for possible 
errors and missing values  through running of frequencies, such that any issues were 
addressed by going back to the data sources to verify the data. The researcher was 
guided by the supervisors and a qualified statistician as an expert in the field to ensure 
GDMP and GCP.  
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The following categories and variables were used in the study:  
 Socio-demographic: age, place of residence, region, and marital status;  
 Reproductive: parity, history of contraceptives;  
 Behavioural: sexual debut, number of lifetime partners, smoking, alcohol, history 
of STIs; and  
 Clinical: family history of cancer, menarche, history of STIs, serology, ART start, 
PAP smear results and VIA results.  
The significance level (alpha or p-value) of the study was set at 0.05. This means that 
if a mean or a proportion from a sample is likely to occur more than alpha then the 
researcher accepts the null hypothesis. In order to establish prevalence of socio-
demographic, behavioural, frequencies distributions were produced for all categorical 
variables and were summarised as proportions. Furthermore, the prevalence of clinical 
abnormalities in cervical cancer screening was established.  
 
A chi-square test was used to establish associations between the outcome variables 
and explanatory variables; age, marital status, age at first sex, age at first 
menstruation, number of live births, number of lifetime partners, smoking, alcohol, 
history of cervical cancer, HIV status, and ART status. 
 
All explanatory variables were coded and categorical variables in order to use bivariate 
logistic and multivariate regression methods. Bivariate logistic regression was used to 
establish relationship between cervical cancer and each explanatory variable using 
chi-square. Multivariate logistic regression was built based on bivariate logistic results 
if explanatory were below significance level of p<0.20. 
 
4.3 RESEARCH RESULTS 
4.3.1 Background characteristics 
A total of 1748 records were initially extracted in line with the inclusion criteria of age 
group 15-49 years. Frequency distribution of baseline demographic characteristics of 
women of reproductive age between 15 and 49 years screened for cervical 
abnormalities at Mbabane Government Hospital in Swaziland in 2014 (n=1748) are 
shown by the Table 4.1. 
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4.3.2 Distribution of socio-demographic factors (n=1748) 
Table 4.1: Distribution of socio-demographic, reproductive, behavioural, clinical 
factors (n=1748) 
Socio-demographic variables Categorisation Frequency Percent 
Age group 
16 to19 years 30 1.7 
20 to24 years 264 15.1 
25 to  29 years 385 22 
30 to34 years 397 22.7 
35 to 39 years 278 15.9 
40 to 44 years 213 12.2 
45 to 49 years 181 10.3 
 
Urban Rural 
Rural 870 49.8 
Urban 878 50.2 
 
Region Name 
Hhohho Region 1,174 67.2 
Lubombo Region 74 4.2 
Manzini Region 468 26.8 
Shiselweni Region 32 1.8 
 
Marital Status 
Divorced 39 2.2 
Married 841 48.1 
Single 839 48 
Widow 24 1.4 
Missing 5 0.3 
 
Age was initially analysed as a continuous variable where it was established that the 
age of patients ranged from 16 to 49 years. The median age of the patients was 32 
years. Age was then categorised into age groups of five-year age bracket as per 
national survey guides on age categorisation. It can also be noted that distribution of 
number of patients screened for cervical abnormalities at age group of 16-19 years 
was lower than other age groups, rose steadily, and with a pick at age group of 30-34 
years then started declining in the following age group of 35-39 years. A graphical 
presentation is shown in Figure 4.1. 
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Figure 4.1: Age group distribution of patients screened for cervical abnormalities 
 
Patients came from all parts of the country. Their locations fall in the four regions of 
the country, namely, Hhohho, Manzini, Lubombo, and Shiselweni regions respectively. 
These patients were mostly referred from their peripheral health facilities to Mbabane 
Government Hospital as the main referral facility for cervical cancer.  
 
The majority of the patients came from Hhohho Region while the minority came from 
Shiselweni Region. The hospital where the study was carried out is located in the 
Hhohho Region, and is closer to the Manzini which might be associated with the higher 
number of patients. Lubombo and Shiselweni regions are quite far from Mbabane 
government referral hospital. There was no difference in distribution of patients by 
location; 50% neither came from rural nor urban locations.  
Not all patients indicated their marital status. Only four had missing status. As a result, 
they were excluded in the description by marital status. About 48% indicated that they 
were single and also the same percentage indicated that they were married. Widows 
indicated the least with one percent. A different picture was established in a study on 
knowledge, attitudes, and demographic factors influencing cervical cancer screening 
30
264
385
397
278
213
181
1.7
15.1 22.0 22.7 15.9 12.2 10.3
0
50
100
150
200
250
300
350
400
450
16 to 19 years 20 to 24 years 25 to  29 years 30 to 34 years 35 to 39 years 40 to 44 years 45 to 49 years
age_group
Frequency Percent
41 
behaviour of Zimbabwean women where the majority (70%) were married while 11% 
were in other relationship status (Mupepi, Sampselle & Johnson, 2011: 946).  
 
4.3.3 Distribution of reproductive factors (N=1747) 
Figure 4.2 below indicates that the majority of the patients have children that are less 
or equals to three while a few patients have less than three children. One patient did 
not indicate the number of children. 
 
 
Figure 4.2: Number of children 
 
The picture above is corroborated by the Central Statistics of Swaziland (2016: 96) 
where the total fertility rate (TFR) is defined as a synthetic measure that denotes the 
number of live births a woman would have if she were subject to the current age-
specific fertility rates throughout her reproductive years (15-49 years) at three children. 
 
4.3.4 Distribution of behavioural factors (N=1748) 
A number of behavioural variables were extracted for analysis, these included sexual 
debut, number of lifetime partners’, smoking, alcohol and history of STIs. Their 
descriptive statistics are shown in Table 4.2. 
 
82.8%
17.1%
less or equal to 3 children above 3 children
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Table 4.2: Distribution of behavioural factors (N=1748) 
Behavioural variables Categorisation Frequency Per cent 
Sexual debut category 
0 to 9 years 3 0.2 
10 to 19 years 1,103 63.1 
20 to 29 years 615 35.2 
Missing 6 0.3 
 
Number of lifetime partners 
0 to 2 892 51 
3 to 5 687 39.3 
6 to 8 73 4.2 
9 to11 52 3 
12 to14 3 0.2 
15 to17 6 0.3 
18to20 4 0.2 
21to23 2 0.1 
Missing 29 1.7 
 
Smoke 
No 1,646 94.2 
Yes 102 5.8 
 
Alcohol 
No 1,561 89.3 
Yes 187 10.7 
 
History of STIs 
No 1,289 73.7 
Yes 459 26.3 
 
Table 4.2 indicates that the majority (63.1%) of patients had their sexual debut 
between the age group 10 to 19 years. A total of 3 patients indicated that they never 
had sex in their lives. When patients were asked on the number of lifetime partners, 
the numbers ranged from zero to 23 and some chose not to respond. The majority 
(51%) of patients indicated that they had two or less partners in their lifetime. About 
two patients indicated that their number of lifetime partners ranged from 21 to 23. 
About 26.3% had history of STIs. Early sexual debut is a measure of youth risk 
behaviour. Delayed sexual debut helps reduce the risk of HIV and AIDS, STIs, risk of 
cervical cancer, and unwanted pregnancies (Central Statistical Office Swaziland, 
2016:251).  
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Patients were asked about smoking habits and 94.2% indicated that they do not 
smoke. About 10.7% of the patients indicated that they take alcohol. According to Park, 
Kim, Seo, Kang and Lim (2016:371), they explored the prevalence of smoking, alcohol 
consumption, physical activity, and obesity in cervical cancer survivors and examined 
associations between socio-demographic factors and each health behaviour. Alcohol 
drinking was negatively correlated with educational level, which is consistent with 
previous data on cancer survivors who had undergone hematopoietic cell 
transplantation. The combination of the above risks could increase the risk of cervical 
cancer. 
 
4.3.5 Distribution of clinical factors (N=1748) 
A number of clinical variables were extracted for analysis. These included HIV status, 
antiretroviral therapy, age at first menstruation, and history of cervical cancer. Their 
descriptive statistics are shown in Table 4.3. 
 
Table 4.3: Distribution of clinical factors (N=1748) 
Clinical variables Categorisation Frequency Per cent 
HIV status 
Negative 1,055 60.4 
Positive 588 33.6 
Missing 105 6.0 
 
On antiretroviral therapy 
No 1,054 60.3 
Yes 364 20.8 
Missing 330 18.9 
   
Age at first menstruation 
10 to14 years 1,090 62.4 
15 to19 years 642 36.7 
20 to 24 years 12 0.7 
Missing 4 0.2 
 
History of cervical cancer 
No 1,565 89.5 
Yes 183 10.5 
 
Table 4.3 indicates that 60.4% patients were HIV negative while 33.6% were HIV 
positive. According to Swaziland Ministry of Health (2017:70), the prevalence of HIV 
among adults aged 15 years and older in Swaziland is 27.0%: 32.5% among females 
and 20.4% among males. This translates to approximately 200,000 people living with 
HIV (PLHIV) aged 15 years and older. About 20.8% indicated to be on antiretroviral 
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therapy, while 18.9% had missing antiretroviral therapy status. About 62.4% of the 
patients had their first menstruation at 10 to 14 years. About 10.5% indicated that they 
had a history of cervical cancer. 
 
4.3.6 Cervical cancer screening using Visual Inspection (n=1748) 
Visual inspection of the cervix after application of 3-5% acetic acid is a potential 
alternative to cytology for screening in low-resource countries. According to Grover, 
Raesima, Bvochora-Nsingo, et al. (2015:2) “See and Treat” (SAT) screening, as an 
alternative to cytology, is performed through visual inspection after acetic acid (VIA) 
application to the cervix followed by immediate treatment with cytotherapy for screen 
positive patients. The study screened for cervical abnormalities using VIA method. 
Initial results from screening are shown first by many individual results and further 
categorised into positive or negative as shown in Table 4.4. 
 
Table 4.4:  Distribution of cervical screening results by method (N=1748) 
Screening Method Category Frequency Per cent 
Visual Inspection result 
Genital warts 1 0.1 
Not Done 249 14.2 
Not reactive 1,255 71.8 
Cervicitis 232 13.3 
Inflammation 2 0.1 
Missing 9 0.5 
 
Visual Inspection result category 
Negative 1,255 71.8 
Positive 235 13.4 
Missing 258 14.8 
 
Table 4.4 shows that the majority (71.8%) of the cases screened negative of cervical 
abnormalities using VIA. About 14.2% cases could not be screened, while nine cases 
had missing results. Notably, 13.3% cases screened positive for cervicitis. The 
different results were then categorised to positive and negative for cervical 
abnormalities. Those that were categorised as positive for cervical abnormalities 
include genital warts, inflammation and cervicitis. Conversely, non-reactive ones were 
categorised as negative for cervical abnormalities. Those not done were added into 
missing and contributed to 14.8%. Eventually, 13.4% screened positive for cervical 
abnormalities, using visual inspection method. The evidence-based SAT approach 
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has been implemented in low-resource settings around the world, such that several 
South African studies have found the approach cost-effective, safe, and efficacious in 
screening for and treating cervical dysplasia (Grover et al. 2015:2). 
 
4.3.7 Cervical cytology screening (N=1748) 
The study also used the Pap test or cyclonical screening methods to establish any 
abnormal changes in cells of the cervix. Results from the screening are categorised 
according to the Bethesda system. The Bethesda system is a list of terms used by 
laboratories to describe Pap test results in several groups, namely, normal, atypical 
squamous cells of undetermined significance (ASCUS), atypical glandular cells 
(AGC), low-grade squamous intraepithelial lesion (LSIL), high grade squamous 
intraepithelial lesion (HSIL), and cancer. Table 4.5 shows a distribution of pap results 
by Bethesda category. 
 
Table 4.5: Cervical cytology screening results (N=1748) 
Category of Bethesda screening results Category Frequency Per cent 
Bethesda results 
Negative 1,440 82.4 
ASCUS 19 1.1 
AGC 25 1.4 
HSIL 138 7.9 
LSIL 54 3.1 
Cancer 2 0.1 
Inflammation 25 1.4 
Missing 45 2.6 
 
Bethesda recoded results 
Negative 1,440 82.4 
Positive 263 15.1 
Missing 45 2.6 
 
Table 4.5 shows that the majority (82.4%) screened negative while 15.1 % screened 
positive for cervical abnormalities from the Pap test. Among those that screened 
positive, a higher percentage (7.9%) showed high grade squamous intraepithelial 
lesions. A few cases (0.1%) had cancer. A total of 45 cases were missing. According 
to the American College of Obstetricians and Gynaecologists Frequently Asked 
Questions161 (2011:2), all patients that screen positive may need further testing 
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depending on age and the grade of the dysplasia. Sometimes there is more than one 
option for further testing, with advice from health care provider. 
 
4.3.8 Association between age group and Bethesda results 
Age group categories were compared with cytology results according to the Bethesda 
categories in order to establish distribution of the results by age group as reflected in 
Table 4.6. 
 
Table 4.6: Association between Age group and Bethesda results 
Age group Negative Inflammation  AGC ASCUS LSIL HSIL cancer Total 
16-19 years 28 0 0 1 0 1 0 30 
20-24 years 220 6 1 4 5 21 0 257 
25-29 years 322 6 2 6 13 27 1 377 
30-34 years 323 6 5 3 15 31 0 383 
35-39 years 227 4 6 0 10 25 0 272 
40-44 years 172 2 7 1 9 17 1 209 
45-49 years 148 1 4 4 2 16 0 175 
Total 1440 25 25 19 54 138 2 1703 
Pearson chi2(36) =  36.6522    Pr = 0.438 
 
In Table 4.6, the age group 30 to 34 years had more cases of both low-grade 
squamous intraepithelial lesions (LSIL) and high-grade squamous intraepithelial 
lesions (HSIL) as compared to the other age groups. Cancer cases were picked in the 
age group 25 to 29 years and age group 40 to 44 years with one cases in each. More 
cases of AGC were shown in the age group 40 to 44 years, while more cases of ACUS 
were established in the age group 25 to 29 years. Seemingly, cases of high-grade 
squamous intraepithelial lesions increased with age of the women, while cases of low-
grade squamous intraepithelial lesions decreased with age. This observation is 
corroborated by Mamahlodi, Kounza and Candy (2011:8) in a study on cervical cancer 
screening programme in Limpopo Province of South Africa that the prevalence of HSIL 
increased with the advancing age of the women (p-value < 0.001). By contrast, the 
rate of LSIL decreased with increasing age (p-value < 0.001). 
 
 
4.3.9 Association between Age and visual inspection results  
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 Age group categories were compared with visual inspection application results in 
order to establish distribution of the results by age group as reflected in Table 4.7. 
 
Table 4.7: Age group distribution of visual inspection application results 
Age group Genital warts Not done Not reactive Cervicitis Inflammation Total 
16-19 years 0 1 24 4 0 29 
20-24 years 1 27 196 38 1 263 
25-29 years 0 40 287 57 0 384 
30-34 years 0 49 278 68 0 395 
35-39 years 0 30 213 32 1 276 
40-44 years 0 39 152 21 0 212 
45-49 years 0 63 105 12 0 180 
Total 1 249 1255 232 2 1739 
Pearson chi2(24)=99.8713   Pr = 0.000 
 
 
Table 4.7 indicates that among the patients screened positive for cervicitis, the 
majority (68) were contributed by age group 30 to 34 years, while age 16 to 19 years 
contributed the least number of cases (4). The one case diagnosed with genital warts 
came from age group 20 to 24 years. VIA picks up more cases probably because of 
the physiological changes in pregnancy.  Therefore, high estrogenic milieu of 
pregnancy causes an increase in cervical volume through hypertrophy of the 
fibromuscular stroma, an increase in the vascularity of the entire lower genital tract, 
more prominent gland opening with tenaciousmucus production, and an increase in 
stromal edema. The endocervical canal also frequently everts onto the ectocervix. The 
endocervical canal also frequently everts onto the ectocervix. The vagina becomes 
more acidic because of higher estrogen levels, and the decidual cells of the cervix 
show an increase in the nuclear-to-cytoplasmic ratio, together with more prominent 
nucleoli (Thilagavathi & Greetha, 2016:65). 
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4.3.10 Prevalence of cervical abnormalities  
Results from VIA and cytological results that were categorised as positive or negative 
were combined to establish overall screening cervical test results as shown in  Figure 
4.3. 
 
 
Figure 4.3: Overall screening cervical test results 
 
Figure 4.3 depicts that the overall prevalence of cervical cytology was 24.9% (CI: 22.9-
26.9), while those that were screened negative were 75.1%. Ferlay et al. (2012:27) 
estimated that cervical cancer morbidity and mortality was at 36.0/100 000 and 
19.1//100 000 women per year respectively. However, it can be noted that Figure 4.3 
shows much lower prevalence. This could be owing to the fact about one in every five 
women aged 30-49 years had ever had a screening test for cervical cancer (Swaziland 
Ministry of Health, 2014:15). 
 
4.3.11 Association between age and overall cervical test results 
Results from VIA and cytological test results that were categorised as positive or 
negative were combined to establish overall screening results as shown in  Table 4.8. 
 
 
 
75.1%
24.9%
Negative Positive
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Table 4.8: Distribution of overall cervical screening results by age group 
Age group Negative Positive Total 
16-19 years 25 5 30 
20-24 years 197 67 264 
25-29 years 286 99 385 
30-34 years 286 111 397 
35-39 years 210 68 278 
40-44 years 163 50 213 
45-49 years 146 35 181 
Total 1313 435 1748 
Pearson chi2(6) = 6.5019 Pr= 0.369 
 
Table 4.8 shows that the distribution of number of patients screened for cervical 
abnormalities at age group of 16-19 years was lower than all other age groups. The 
numbers of cervical abnormalities increase with age until age group of 30-34 years 
where it starts to decrease. This could be owing to high HIV prevalence among 
females in Swaziland (Swaziland Ministry of Health, 2014:15). 
 
4.3.12 Association between cervical abnormalities and risk factors 
Bivariate logistic regression was used to establish relationship between cervical 
cancer and each explanatory variable using chi-square. 
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Table 4.9: Association between cervical abnormalities and risk factors 
Risk factor OR Chi2 P-Value 95 per cent CI 
Young and Old       0.96 0.21 0.22 0.89 - 1.02 
Urban and Rural 0.97 0.08 0.78 0.78 - 1.20 
Region and No region 0.99 0.02 0.90 0.88 - 1.11 
Married and unmarried 1.23 4.36 0.04 1.01 -1.49 
Early sexual debut and 
Delayed sexual debut 0.72 8.47 0.00 0.58 - 0.90 
Few number of lifetime 
partners and Many number of 
lifetime partners 1.07 1.03 0.31 0.94 - 1.21 
Smoking and Not smoking 1.64 3.98 0.08 0.94 - 2.84 
Drink alcohol and Not drink 
alcohol 0.93 0.11 0.76 0.60 - 1.45 
History of STIs and No history 
of STIs 1.22 2.54 0.11 0.96- 1.55 
HIV positive and HIV negative 2.11 51.01 0.00 1.61 - 2.75 
On antiretroviral therapy and 
On no antiretroviral therapy 2.09 28.42 0.00 1.60- 2.72 
Early menstruation and Late 
menstruation 0.84 2.56 0.18 0.65 - 1.08 
History of cervical cancer and 
No history of cervical cancer 1.01 0.08 0.94 0.68 - 1.51 
 
Table 4.9 demonstrates that patients that were married were 1.23 times (CI: 1.01 -
1.49) likely to have cervical abnormalities than unmarried patients. HIV positive 
patients were 2.11 times (CI: 1.61 - 2.75) likely to have cervical abnormalities than HIV 
negative patients. Patients on antiretroviral therapy were 2.09 times (CI: 1.60- 2.72) 
likely to have cervical abnormalities than those not on ART. Patients who delayed 
sexual debut were 0.72 times (0.58 - 0.90) likely to have cervical abnormalities than 
those who had an early sexual debut. According to Baussano, Diaz, Tully, Muñozc, de 
Sanjosé, Bosch and  Franceschi (2017: 104), early age at first sexual intercourse has 
been associated with an increased risk of high HPV infection, a sexually transmitted 
infection, that in susceptible women virtually all cases of invasive cervical cancer. 
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4.4 OVERVIEW OF RESEARCH FINDINGS 
The study results revealed that the overall prevalence of cervical cytology test results 
was 24.9%. This is in line with assertion by Swaziland Ministry of Health (2016:12) 
that the country is not sparred from the burden related to cervical cancer among 
women. It is the first most common malignancy in women accounting for 31% of all 
female cancers.  The prevalence of cervical cytology could be more since it was 
reported that about one in every five women aged 30-49 years had ever had a 
screening test for cervical cancer (Swaziland Ministry of Health, 2014:15). About 
13.3% cases screened positive for cervical abnormalities using VIA, while 15.1 % 
screened positive for cervical abnormalities from the Pap test.  
 
A number of studies have identified risk factors associated with cervical abnormalities. 
However, this study indicates that being married, being HIV positive, age at sexual 
debut and being on ART were associated with cervical abnormalities. Marriage is 
expected to be a protective factor for cervical abnormalities; however, being married 
increased the odds (OR=1.23, p= 0.04). Delaying sexual intercourse at a young age 
minimises the chances of cervical abnormalities (OR=0.72, p=0.00). Bahmanyar et al. 
(2012:443) corroborate this in the PATRICIA trial that there was a significant 
association between several behavioural risk factors and infection with cervical 
cancer.  Women who are HIV positive are at particular risk of progression to invasive 
cervical cancer. The study established that being HIV positive (OR=2.11, p= 0.00) and 
on ART (OR=2.09, p= 0.00) was associated with cervical abnormalities.  According to 
The Lancet (2017:856), lowered immune system can be caused by immune 
suppression from corticosteroid medications, organ transplantation, treatments for 
other types of cancer, or from HIV and AIDS. Risk factors including number of lifetime 
partners, smoking, history of STIs and history of cervical cancer had higher odds of 
cervical abnormalities, but were not significant. 
 
4.5 CONCLUSION 
This chapter focused on analysis, presentation and description of main research 
findings of the study. These results were introduced by the presentation and 
discussion of the characteristics of the respondents. Bivariate and multivariate logistic 
regression were used to establish relationship between cervical cancer and each 
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explanatory variable.  The next chapter will discuss these findings and conclusions 
and make recommendations based on them.  
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CHAPTER 5  
CONCLUSIONS AND RECOMMENDATIONS 
 
5.1 INTRODUCTION 
Chapter 4 focused on analysis, presentation and description of main research findings 
of the study. This chapter presents the conclusions and recommendations of the study. 
The purpose of the study was to explore and describe factors associated with cervical 
cancer among women of reproductive age between 15 and 49 years in Swaziland. 
Focus was on the conclusions of the research in relation to the research questions 
asked and specifically the problem statement. Limitations of the study are limited to 
generalizability of the findings. 
 
5.2 RESEARCH DESIGN AND METHOD 
A chi-square test was used to establish associations between the outcome variables 
and explanatory variables. Having cervical cancer or not was used as an outcome 
variable, while explanatory variables included socio-demographic, reproductive, 
behavioural ad clinical variables. All explanatory variables were coded as categorical 
variables in order to use bivariate logistic and multivariate regression methods. 
Bivariate logistic regression was used to establish relationship between cervical 
cancer and each explanatory variable using chi square.  
 
5.3 SUMMARY AND INTERPRETATION OF THE RESEARCH FINDINGS 
 
5.3.1 Distribution of socio-demographic factors 
The median age of the patients was 32 years. The distribution of number of patients 
screened for cervical abnormalities at age group of 16-19 years was lower than other 
age groups. Nevertheless, it rose steadily, and with a pick at age group of 30-34 years 
then started declining in the following age group of 35-39 years. The majority of the 
patients came from Hhohho Region while the minority came from Shiselweni Region. 
The majority were either single or married.  
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5.3.2 Distribution of reproductive factors 
The majority of the patients had children that were less or equals to three while a few 
patients had less than three children.  
 
5.3.3 Distribution of behavioural factors 
The majority of patients had their sexual debut between the age group 10 to 19 years, 
while three indicated that they never had sex in their lives. The majority (51%) of 
patients indicated that they had two or less partners in their lifetime. About two patients 
indicated that their number of lifetime partners ranged from 21 to 23. Patients were 
asked about smoking habits; 94.2% indicated that they do not smoke. About 10.7% of 
the patients indicated that they take alcohol. About 26.3% had history of STIs. 
 
5.3.4 Distribution of clinical factors 
About 60.4% patients were HIV negative while 33.6% were HIV positive. About 20.8% 
indicated to be on antiretroviral therapy, while 18.9% had missing antiretroviral therapy 
status. About 62.4% of the patients had their first menstruation at 10 to 14 years. About 
10.5% indicated that they had a history of cervical cancer. 
 
5.3.5 Cervical cancer screening using Visual Inspection 
About one in ten patients screened positive while seven in ten screened negative for 
cervical abnormalities using the VIA method. Others had missing results. 
 
5.3.6 Cervical cytology screening 
The majority (82.4%) screened negative while 15.1 % screened positive for cervical 
abnormalities from the Pap test. Among those that screened positive, a higher 
percentage (7.9%) showed high grade squamous intraepithelial lesions. A few cases 
of patients (0.1%) had cancer. 
 
5.3.7 Association between age group and Bethesda results 
The age group 30 to 34 years had more cases of both LSIL and HSIL as compared to 
the other age groups. Cancer cases picked in the age group 25 to 29 years and age 
group   40 to 44 years with one cases in each. More cases of AGC were shown in the 
age group 40 to 44 years, while more cases of ACUS were established in the age 
group 25 to 29 years. 
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5.3.8 Association between age and visual inspection results 
Among the patients screened positive for cervicitis, the majority (68) were contributed 
by age group 30 to 34 years, while age 16 to 19 years contributed the least number of 
cases (4). The one case diagnosed with genital warts came from age group 20 to 24 
years. 
 
5.3.9 Prevalence of cervical abnormalities 
The study results revealed that the overall prevalence of cervical cytology test results 
was 24.9%. 
 
5.3.10 Association between Age and overall cervical test results 
The number of patients screened for cervical abnormalities at age group of 16-19 
years was lower than all other age groups. The highest number of cervical 
abnormalities were recorded at age group of 30-34 years. 
 
5.3.11 Association between cervical abnormalities and risk factors 
The combination of marital status, HIV status, ART status, age at sexual debut have 
been identified as factors associated with cervical abnormalities. Patients that were 
married were 1.23 times (CI: 1.01 -1.49) likely to have cervical abnormalities than 
unmarried patients. HIV positive patients were 2.11 times (CI: 1.61 - 2.75) likely to 
have cervical abnormalities than HIV negative patients. Patients on antiretroviral 
therapy were 2.09 times (CI: 1.60- 2.72) likely to have cervical abnormalities than 
those not on ART. Patients who delayed sexual debut were 0.72 times (0.58 - 0.90) 
likely to have cervical abnormalities than those who had an early sexual debut. 
 
5.4 CONCLUSIONS 
Results from the study imply that the combination of marital status, HIV status, ART 
status, age at sexual debut have been identified as factors associated with cervical 
abnormalities. Therefore, more attention is needed to consider or even address some 
of these factors when designing sexual reproductive services, especially cervical 
cancer screening.  
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5.5 RECOMMENDATIONS 
Based on the findings of the study, the following recommendations are made: 
 In response to cervical cancer being leading among female cancers and also 
increasing cases, there is a need to strengthen cervical cancer screening and 
prevention to become an essential part of a comprehensive sexual and 
reproductive health services for women. 
 HIV services should be integrated into the Gynaecology Department in order to 
improve early diagnosis and cervical abnormalities treatment outcomes. The 
screening programme needs to be evaluated. 
 The age group 30-34 has the highest number of cases with cervical abnormalities. 
Therefore, there should be a targeted study focusing on why the high cases using 
qualitative methods.  
 Future research should be rolled out to public health units especially in rural areas 
for more access and coverage.  
 Special programmatic needs on cervical cancer prevention are required 
considering that the country has about 13% of women with cervical abnormalities. 
 
5.6 CONTRIBUTIONS OF THE STUDY 
Because of the retrospective nature of the study, the researcher was able to establish 
the magnitude and factors associated with cervical abnormalities, therefore providing 
evidence to help plan cervical cancer screening coverage. The results will also serve 
as evidence for the development of a national cervical cancer screening policy and 
also strengthening the cancer registry in Swaziland.  
 
5.7 LIMITATIONS OF THE STUDY 
This study made use of secondary data and the general limitation was using variables 
that exist. The objectives were therefore streamlined according to the information 
available, despite wanting a detailed analysis for completeness. A significant number 
of records on HIV and ART status were missing owing to the lack of offer of HIV 
services in the Gynaecology Department. The study is limited to cervical cases in 
Mbabane Government Hospital and those diagnosed from January 2014 through to 
December 2014 only. The study was limited to extraction of patients’ data without an 
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interaction with them. The researcher could not determine the sample size as the study 
sample size was dependent on the aggregated data available in the data warehouse. 
 
5.8 CONCLUDING REMARKS 
In order to meet the Sustainable Development Goals for sexual reproductive health, it 
is vital that the cervical cancer be further minimised by advancing cervical cancer 
screening services for women in Swaziland.  
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Annexe B: Letter seeking consent from the Department of Health in Swaziland 
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Annexe C: Letter of approval: Department of Health in Swaziland 
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Annexe D: Assessment of data collection instrument 
 
 
  
FACILITY CODE REGION CODE
1. NEW CASE FOLLOW UP
2. STUDY ID Number 3. Marital Status  (1Single/2not single)
4. Contact number(patient)  5. Alternative contact (NoK)
6. Age 7.  Date of birth d d m m y y y 8. Sex [1=male 2=female 9=unknown]
10. Race (Black= 1 , White=2, Asian= 3, Colored=4,Other=9 ) 11. Religion (christianity, muslim, Hindu, other ) …………………………………..
12. Education level ……………………………………………………………. 13. Occupation …………………………………………………………………………………………
B. Risk Factors/ Other Diseases
Previous Cancer Diagnosis
14. Was cancer disgnosed previously other than the current  ( 1 - Yes, 2 - No, 9 - Unknown)
If Yes, Date of diagnosis d d m m y y y
Site/Topography C . Histology/Morphology /
15. Smoking ( 1 - Yes, 2 - No, 9 - Unknown) 16. Alcohol (1 - Yes, 2 - No, 9 - Unknown)
If Yes, No. of cigars per day 17. History of contraceptives
18. History of CA 19. Serology
20. HIV Status (1 - Negative, 2 Positive, 0 - Unknown) If Positive, is patient on ART (1 - Yes, 2 - No, 9 - Unknown)
If on ART, ART number 21. History of STIs
22.Time started on ART 23. Sexual Onset (year) 24. Menarche
25.  Family history of cancer (1 - Yes, 2 - No, 9 - Unknown) 26.Number of Lifetime partners 27.PAP result
28. # of lifetime partners 29.VIA result 30.CRYO
Other Diseases …………………………………………………………………………………………………………………………………………………………………………………….…………...
C. TUMOUR
31. Duration of Symptoms days months years
32. Basis of diagnosis (0 death cert only,  1 clinical only,   2 clinical/ultrasound,   3 biochem Immuno test,   4 cytology/haematology
    5 Histology of metastasis,  6 Histology of primary,  7 unknown)
33. Primary site of the tumors ………..C
34. Laterality     Rt Lt Bil Unk N/A
35. Histology ……………………………………………..………….…………………………...……….………………………………..………………………………… M
36. Behaviour 37. Grade  38.Stage T  ………………………
0-Benign 1-  well-diff                    5- poorly diff 0-In situ
1-uncertain 2 - moderately diff       6-b-cell                                         1- stage 1 N  ………………………
2-in situ 3-  undiffrrentiated/    7- Null cell 2- stage 2
3-Malignant Anaplastic                8- Killer cell                                   3- stage 3 M  ………………………
4- T-cell                           9- unknown 4- stage 4
9- unknown
D.TREATMENT
39. FIRST COURSE OF TREATMENT: [1=NO; 2=YES;9=UNKNOWN]
Surgery              Date d d m m y y y y Radiotherapy    Date d d m m y y y
Chemotherapy    Date d d m m y y y y Hormone therapy    Date d d m m y y y
Immunotherapy    Date d d m m y y y y Other    Date d d m m y y y
Remarks if any …………………………………………………………………………………………………………………………………………………………………………………………………
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